Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib may leads to lower serious adverse events (Grade 3 or 4) compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).
1 finding from 1 review
- RR 0.74 [0.59, 0.95]1 study · 334 participantsLow